Kevin Adam is a litigation partner in White & Case’s Boston and New York offices and a core member of the Firm’s Global Antitrust/Competition Group. Kevin is a trial lawyer who litigates complex matters at the cutting edge of antitrust and intellectual property, including class actions and competitor lawsuits involving innovation, technology, and pharmaceuticals. He also counsels global clients on a broad range of challenging competition matters, such as pricing practices, licensing and co-development agreements, government investigations, and evolving legislative and regulatory developments. Kevin is a member of the Firm’s Global Pharmaceuticals/Healthcare and Technology Industry Groups and a thought leader on antitrust issues and class actions. He has published more than thirty articles on developments in these areas over the last ten years and co-authored a book on class actions titled "Deconstructing Rule 23: A Comparison of Massachusetts and Federal Class-Action Litigation." In 2021, Kevin was selected to Law360’s Competition Editorial Advisory Board. He is also a member of the ABA Antitrust Section’s Pricing Conduct Committee Advisory Board. Kevin has an extensive pro bono practice, with a focus on criminal appellate work and wrongful convictions. He has represented criminal defendants in federal and state court, successfully overturning a number of convictions in New York’s appellate divisions and securing a jury verdict for a wrongfully convicted man in federal court in Massachusetts. He also works closely with the New England Innocence Project. Kevin graduated from Suffolk University Law School summa cum laude in 2012 and was the Editor-in-Chief of the Suffolk University Law Review. He has also completed executive-level courses in economics at the MIT Sloan School of Management and in global business and negotiation at Harvard Business School. Prior to joining the firm, Kevin worked at the First District Court of Essex County in Salem, Massachusetts and served as a research assistant for the Honorable John M. Greaney, former Associate Justice of the Supreme Judicial Court of Massachusetts.
The US Congress introduces a package of bills seeking changes to antitrust and patent law in the pharmaceutical industryConcurrences Bulletin, Michael Gallagher, Kevin Adam and Ada Yue Wang, 21 April 2021, e-Competitions
US courts annual review: Third circuit, pharmaceutical casesGlobal Competition Review Insight, Noah A. Brumfield, J. Mark Gidley, Kevin C. Adam, Alyson Cox Yates and Mark Levy, July 6, 2020
Why a surge in drug pricing litigation is unlikelyWhite & Case Publications & Events, Lauren Papenhausen, Karen Eisenstadt and Kevin C. Adam, July 28, 2020